Exelixis’s Cabometyx Positive for First-Line Kidney Cancer

0 Comments 1 view(s)

Exelixis, Inc. EXEL announced results from an analysis of the data from the phase II trial, CABOSUN. The study compared Cabometyx to Pfizer’s PFE Sutent in the first-line treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC) patients.

read more